West Pharmaceutical Services (WST) Receivables (2009 - 2026)

West Pharmaceutical Services has disclosed Receivables across 18 years of filings, most recently posting $701.0 million for Q1 2026.

• Receivables for Q1 2026 came in at $701.0 million, up 23.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $701.0 million (up 23.11% YoY), and the FY2025 annual result was $586.3 million, up 1.82% from the prior year.
• Receivables came in at $701.0 million for Q1 2026 at West Pharmaceutical Services, up from $586.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $701.0 million in Q1 2026 to a low of $502.0 million in Q2 2024.
• The 5-year median for Receivables is $543.9 million (2024), against an average of $561.9 million.
• Across the five-year window, Receivables declined 9.68% in 2024 and climbed 23.11% in 2026, its largest moves.
• West Pharmaceutical Services' Receivables stood at $523.7 million in 2022, then rose by 1.87% to $533.5 million in 2023, then increased by 7.93% to $575.8 million in 2024, then gained by 1.82% to $586.3 million in 2025, then gained by 19.56% to $701.0 million in 2026.
• The last three Receivables figures came in at $701.0 million (Q1 2026), $586.3 million (Q4 2025), and $652.5 million (Q3 2025), per Business Quant data.